OR WAIT null SECS
April 09, 2009
Also, Genzyme and Bayer HealthCare form agreement; FDA releases draft guidances; TransMolecular appointed Robert Radie president and CEO
April 08, 2009
The financial crisis is adding further injury to already weakened prospects for the pharmaceutical industry.
Follow-on biologics or biosimilars offer a niche growth market for the pharmaceutical industry. As the process for establishing a regulatory pathway for biosimilars is debated, companies, including Big Pharma, are positioning themselves to gain this piece of the pharmaceutical pie.
April 02, 2009
The US Senate introduced a bipartisan bill (S. 726) on Mar. 26, 2009, which establishes a regulatory pathway for approval of biosimilars.
Also, SOCMA changes name; two FDA approvals; Biogen Idec names chief operating officer; more...
Obama's cost-containment and science-innovation initiatives need to overlap.
A review of recent product innovations, policy developments, and growth prospects in the excipients market.
The financial and economic downturn is likey to have long-term implications for outsourcing.
April 01, 2009
The authors demonstrate how melt-extrusion and spray-drying methods can help to prepare solid dispersions of poorly soluble drugs using Eudragit polymers.
The authors examine common superdisintegrants (i.e., crospovidone Type A, crospovidone Type B, croscarmellose sodium, and sodium starch glycolate) with a set of poorly soluble drug actives and evaluate in vitro drug dissolution.